Cyclo Therapeutics Inc. (CYTH) Fundamentals

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its lead drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex.
SHARE INFORMATION
Market Cap$ 16,664,773
Shares Outstanding8,416,552
Float7,653,098
Percent Float90.93%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 1,585,756
Latest Fiscal EPS$ -2.26
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions29
Institutional Holdings Date2022-04-30
Institutional Bought Previous 3 Months143,055
Institutional Holdings Percent11.9%
Institutional Sold Previous 3 Months15,316
Insider Holdings Date2022-03-31
Insider Bought Previous 3 Months248,132
Insider Holdings Percent0.0
Insider Sold Previous 3 Months-
Insider Shares Owned18,678,758
TRADING INFO
52 Week High$ 13.00
52 Week Low$ 1.88
52 Week High Change$ -73.56
21 Day Moving Average$ 2.3967
21 Day Extended Moving Average$ 2.3333
50 Day Moving Average$ 2.6907
50 Day Extended Moving Average$ 2.6952
200 Day Moving Average$ 4.7537
200 Day Extended Moving Average$ 4.3564
10 Day Average Volume23,079
20 Day Average Volume26,054
30 Day Average Volume27,848
50 Day Average Volume46,514
Alpha-0.015745
Beta0.4583
Standard Deviation0.198795
R20.010014
7 Day Price Change$ -0.13
7 Day Percent Change-6.16%
21 Day Price Change$ -0.70
21 Day Percent Change-26.12%
30 Day Price Change$ -0.96
30 Day Percent Change-32.65%
Month to Date Price Change$ -0.70
Month to Date Percent Change-26.12%
Quarter to Date Price Change$ -1.19
Quarter to Date Percent Change-37.54%
180 Day Price Change$ -3.29
180 Day Percent Change-62.43%
200 Day Price Change$ -4.05
200 Day Percent Change-67.16%
Year to Date Price Change$ -1.75
Year to Date Percent Change-46.92%

Cyclo Therapeutics Inc. (CYTH) Key Ratios

PROFITABILITY
EBIT Margin-925.5%
EBITDA Margin-924.2%
Pre-Tax Profit Margin-589.1%
Profit Margin Count0.0%
Gross Margin90.3%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 1,422,527
Revenue Per Share$ 0.169
Revenue (3 Years)$ 12.94
Revenue (5 Years)$ -0.07
FINANCIAL STRENGTH
Price to Tangible Book1.30
Total Debt To Equity0.00
Int Coverage0.00
Current Ratio5.50
Leverage Ratio1.30
Quick Ratio4.20
Long Term Debt To Capital0.00
VALUATION MEASURES
PE Ratio-1.10
Enterprise Value$ 4,880,776
Price to Sales11.7149
Price to Free Cash-1.10
PE High Last 5 Years-2.70
Price To Book1.30
Price To Cash Flow63.20
PE Low Last 5 Years-5.00
Price to Tangible Book1.30
MANAGEMENT EFFECTIVENESS
Receivables Turnover3.50
Invoice Turnover0.60
Assets Turnover0.10
Return Assets-76.45
Return on Equity-95.15
Return on Capital-94.83

Cyclo Therapeutics Inc. (CYTH) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorWithumSmith+Brown, PC
CEON. Scott Fine
Emplyoees9
Last AuditUQ
CIK0000922247
IndustryDrug Manufacturers
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address6714 NW 16th Street
Suite B
Gainesville, FL 32653
Websitehttps://www.cyclodex.com
Facsimile+1 321 244-8351
Telephone+1 386 418-8060
Emailinfo@cyclotherapeutics.com


Your Recent History
NASDAQ
CYTH
Cyclo Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.